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Atherosclerosis:	  chronic	  inflammation	  in	  the	  artery	  wall	  Atherosclerosis	  is	  a	  maladaptive,	  non-­‐resolving	  chronic	  inflammatory	  disease	  that	  occurs	  at	  sites	  of	  blood	  flow	  disturbance.	  	  The	  atherogenic	  process	  is	  thought	  to	  be	  triggered	  by	  the	  subendothelial	  retention	  of	  cholesterol-­‐containing	  plasma	  lipoproteins	  at	  these	  sites	  and	  by	  flow-­‐mediated	  inflammatory	  changes	  in	  endothelial	  cells	  1,	  2	  .	  	  The	  lesions	  contain	  monocyte-­‐derived	  macrophages	  and	  T	  cells	  interspersed	  with	  acellular	  regions	  containing	  lipids	  and	  debris	  from	  dead	  cells,	  embedded	  in	  an	  extracellular	  matrix	  composed	  of	  collagen	  fibers	  and	  other	  constituents	  produced	  primarily	  by	  vascular	  smooth	  muscle	  cells3,	  4.	  The	  collagenous	  matrix	  typically	  forms	  a	  fibrous	  cap	  that	  overlies	  the	  lipid	  rich	  region	  in	  the	  plaque	  core.	  	  Lesions	  generally	  remain	  covered	  by	  an	  intact	  endothelium	  until	  the	  late	  stages	  of	  the	  disease.	  The	  eventual	  breakdown	  of	  endothelial	  continuity	  can	  promote	  lesion	  progression	  and	  complication.	  Cells	  of	  the	  atherosclerotic	  lesion	  display	  features	  of	  ongoing	  inflammation,	  with	  macrophages	  and	  T	  cells	  producing	  a	  host	  of	  mediators	  including	  proinflammatory	  cytokines,	  costimulatory	  factors	  for	  immune	  activation,	  eicosanoids,	  and	  reactive	  oxygen	  and	  nitrogen	  species	  5,	  6.	  In	  addition,	  many	  of	  the	  macrophages	  internalize	  cholesterol	  through	  their	  scavenger	  receptors	  and	  some	  also	  produce	  anti-­‐inflammatory	  cytokines.	  Furthermore,	  certain	  T	  cells	  of	  the	  regulatory	  phenotype	  display	  anti-­‐inflammatory	  and	  immunosuppressive	  features.	  This	  delicate	  balance	  between	  pro-­‐	  and	  anti-­‐inflammatory	  signals	  results	  in	  a	  slowly	  progressive,	  non-­‐resolving,	  chronic	  inflammation7.	  	  
Innate	  and	  adaptive	  reactions	  in	  the	  artery	  Several	  reactions	  link	  lipid	  accumulation	  to	  inflammation.	  In	  the	  macrophage,	  pattern	  recognition	  receptors	  selected	  in	  evolution	  for	  handling	  components	  of	  microbial	  pathogens	  also	  mediate	  internalization	  of	  modified	  lipoproteins5,	  6.	  These	  scavenger	  receptors	  evade	  suppression	  due	  to	  increases	  in	  intracellular	  cholesterol	  concentrations,	  and	  can	  therefore	  mediate	  continued	  lipoprotein	  uptake	  that	  permits	  overloading	  the	  cell	  with	  lipids.	  At	  a	  certain	  point,	  intracellular	  cholesterol	  precipitates	  as	  microcrystals.	  Analogously	  with	  urate	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crystals,	  these	  cholesterol	  microcrystals	  can	  activate	  an	  inflammasome,	  i.e.	  a	  cytosolic	  molecular	  machine	  that	  cleaves	  a	  proform	  of	  interleukin	  (IL)-­‐1	  beta,	  converting	  it	  into	  bioactive	  IL-­‐1beta	  that	  can	  be	  secreted	  by	  the	  cell8.	  When	  released	  in	  the	  arterial	  intima,	  IL-­‐1beta	  induces	  production	  of	  a	  set	  of	  other	  proinflammatory	  molecules,	  including	  the	  cytokine	  IL-­‐6	  and	  the	  proinflammatory	  eicosanoid,	  PGE29,	  10.	  IL-­‐1	  beta	  also	  promotes	  expression	  of	  leukocyte	  adhesion	  molecules	  and	  matrix-­‐degrading	  metalloproteinases.	  Thus,	  cholesterol	  accumulation	  begets	  inflammation	  and	  tissue	  remodelling.	  Another	  set	  of	  pattern	  recognition	  receptors,	  the	  Toll-­‐like	  receptors,	  may	  bind	  modified	  lipoprotein	  particles	  in	  the	  arterial	  intima11-­‐14,	  triggering	  phosphorylation	  cascades	  that	  elicit	  expression	  of	  a	  set	  of	  proinflammatory	  genes	  similar	  but	  not	  identical	  to	  that	  elicited	  by	  IL-­‐1	  beta.	  For	  instance,	  TNF	  induces	  expression	  of	  matrix	  metalloproteinases	  that	  degrade	  collagen	  and	  promotes	  tissue	  remodelling15.	  TNF	  has	  crucial	  pathogenetic	  importance	  in	  rheumatoid	  arthritis	  and	  other	  inflammatory	  diseases	  and	  also	  impacts	  atherosclerosis	  substantially	  16-­‐18.	  	  Presentation	  by	  dendritic	  cells	  of	  fragments	  of	  LDL	  particles	  to	  T	  cells	  in	  lymph	  nodes	  draining	  the	  atherosclerotic	  lesion	  calls	  adaptive	  immunity	  into	  action	  19,	  20.	  Clones	  of	  T	  cells	  that	  recognize	  peptide	  fragments	  of	  the	  main	  LDL	  apoprotein	  	  (apoprotein	  B)	  that	  can	  act	  as	  autoantigens.	  	  This	  encounter	  tends	  to	  differentiate	  the	  T	  cells	  into	  proinflammatory	  Th1	  effector	  cells	  under	  the	  influence	  of	  proinflammatory	  mediators	  such	  as	  IL-­‐12	  found	  in	  plaque20,	  21.	  Effector	  T	  cells	  patrol	  the	  body,	  enter	  at	  sites	  such	  as	  the	  plaque,	  where	  endothelial	  cells	  express	  leukocyte	  adhesion	  molecules.	  	  These	  T	  cells	  may	  undergo	  reactivation	  by	  LDL	  fragments.	  Such	  renewed	  activation	  prompts	  the	  Th1	  cell	  to	  produce	  large	  amounts	  of	  TNF	  and	  also	  another	  proinflammatory	  cytokine,	  interferon-­‐gamma	  21,	  22.	  This	  interferon	  strongly	  stimulates	  macrophages	  and	  also	  profoundly	  effects	  vascular	  endothelial	  and	  smooth	  muscle	  cells,	  causing	  them	  to	  express	  leukocyte	  adhesion	  molecules,	  modulate	  their	  fibrinolytic	  properties,	  reduce	  proliferation,	  and	  in	  the	  case	  of	  the	  smooth	  muscle	  cell,	  inhibit	  fibrillar	  collagen	  formation23,	  24.	  	  Interestingly,	  in	  keeping	  with	  the	  counterbalancing	  forces	  mentioned	  above,	  lesional	  dendritic	  cells	  can	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also	  promote	  the	  development	  of	  pro-­‐resolving	  regulatory	  T	  cells	  in	  early	  atherosclerosis25,	  26	  ,	  but	  ultimately	  the	  effector:regulatory	  T	  cell	  balance	  promotes	  progressive	  inflammation.	  In	  the	  advanced	  atherosclerotic	  plaque,	  infiltrating	  mast	  cells	  contribute	  to	  the	  proinflammatory	  milieu27.	  Upon	  activation,	  these	  cells	  release	  a	  host	  of	  mediators	  and	  enzymes,	  including	  histamine,	  serotonin,	  thromboxane	  and	  other	  eicosanoids,	  cytokines,	  and	  a	  set	  of	  serine	  proteases,	  all	  of	  which	  may	  profoundly	  affect	  the	  atherosclerotic	  lesion.	  The	  concerted	  action	  of	  all	  proinflammatory	  signals	  operating	  in	  the	  plaque	  not	  only	  enhances	  inflammation	  but	  also	  hampers	  renewal	  of	  the	  structural	  elements	  that	  support	  the	  mechanical	  stability	  of	  the	  inflamed	  tissue.	  
Clinical	  and	  histopathological	  features	  of	  culprit	  lesions	  The	  atherosclerotic	  process	  typically	  lies	  silent	  for	  months,	  years,	  and	  even	  decades,	  and	  may	  never	  result	  in	  clinical	  manifestations2.	  Yet,	  if	  the	  plaque’s	  surface	  is	  damaged,	  thrombotic	  occlusion	  of	  the	  artery	  may	  ensue.	  Surface	  continuity	  may	  be	  damaged	  by	  fissuring	  (so-­‐called	  plaque	  rupture,	  observed	  in	  60	  to	  80%	  of	  cases	  of	  acute	  coronary	  syndrome)	  or	  surface	  erosion	  (present	  in	  20	  to	  40%	  of	  cases	  with	  coronary	  thrombosis,	  especially	  in	  women	  and	  young	  victims	  of	  sudden	  coronary	  death)28,	  29.	  	  Figures	  1-­‐2	  depict	  these	  two	  different	  types	  of	  discontinuity	  of	  the	  plaque	  surface.	  Recent	  studies	  suggest	  that	  the	  proportion	  of	  infarctions	  caused	  by	  rupture	  vs	  erosion	  is	  changing,	  with	  more	  cases	  due	  to	  erosion	  and	  fewer	  to	  overt	  plaque	  rupture30.	  Fissures	  and	  erosions	  trigger	  atherothrombosis	  by	  exposing	  thrombogenic	  material	  inside	  the	  plaque,	  such	  as	  phospholipids,	  tissue	  factor,	  and	  matrix	  molecules,	  to	  platelets	  and	  coagulation	  factors2.	  Platelet	  aggregates	  precipitating	  on	  these	  exposed	  surfaces	  are	  stabilized	  by	  fibrin	  networks.	  Tissue	  factor,	  expressed	  by	  macrophages	  and	  by	  vascular	  smooth	  muscle	  cells	  in	  the	  atherosclerotic	  plaque,	  can	  initiate	  the	  blood	  coagulation	  cascade	  that	  leads	  to	  fibrin	  formation31.	  Atherothrombi	  expand	  rapidly	  and	  can	  fill	  the	  lumen	  within	  minutes,	  thereby	  leading	  to	  ischemia	  and	  infarction.	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A	  range	  of	  factors	  may	  contribute	  to	  atherothrombosis.	  Disturbance	  of	  the	  balance	  between	  prothrombotic	  and	  fibrinolytic	  activity	  on	  the	  plaque	  surface	  probably	  plays	  an	  important	  role	  for	  precipitating	  the	  thrombotic	  event32,	  but	  the	  precise	  sequence	  of	  events	  that	  operate	  in	  vivo	  is	  not	  yet	  known.	  
The	  “vulnerable	  plaque”	  Thrombi	  precipitate	  on	  damaged	  vascular	  surfaces,	  as	  recognized	  by	  Rudolf	  Virchow	  in	  185633.	  The	  cause	  of	  the	  damage	  leading	  to	  plaque	  rupture	  or	  erosion	  remains	  incompletely	  understood,	  despite	  considerable	  progress	  in	  this	  regard.	  Constantinides,	  Davies,	  Falk	  and	  their	  colleagues	  observed	  that	  ruptured	  plaques	  display	  thin	  fibrous	  caps	  and	  large	  lipid	  core	  regions34-­‐36.	  These	  findings	  highlighted	  structural	  abnormalities	  in	  the	  vessel	  wall	  as	  a	  cause	  of	  atherothrombosis.	  Subsequent	  investigations	  have	  revealed	  that	  culprit	  lesions	  of	  fatal	  thrombi	  in	  coronary	  arteries	  contain	  reduced	  amounts	  of	  mature,	  crosslinked	  collagen	  and	  increased	  levels	  of	  collagen-­‐degrading	  enzymes.	  	  In	  vivo	  imaging	  technology	  now	  offers	  approaches	  to	  the	  analysis	  of	  major	  plaque	  components.	  	  For	  example,	  optical	  coherence	  tomography	  (OCT)	  and	  magnetic	  resonance	  imaging	  can	  identify	  thin-­‐cap	  plaques.	  	  Computerized	  tomographic	  angiography	  can	  identify	  outward	  arterial	  remodelling,	  radiolucency,	  and	  spotty	  calcification	  associated	  with	  coronary	  events.	  Such	  approaches,	  albeit	  incompletely	  validated,	  currently	  see	  used	  to	  obtain	  surrogate	  endpoint	  data	  on	  effects	  of	  putative	  plaque-­‐stabilizing	  therapies37-­‐39.	  Histopathologic	  analysis	  of	  lesions	  that	  have	  provoked	  fatal	  myocardial	  infarction	  (MI)	  shows	  stimata	  of	  inflammation	  including	  accumulation	  of	  macrophages,	  activated	  T	  cells,	  dendritic	  cells,	  and	  mast	  cells	  as	  well	  as	  reduced	  thickness	  of	  the	  fibrous	  cap	  and	  increased	  neovascularization	  at	  sites	  of	  plaque	  rupture	  and	  thrombosis40	  (Fig.	  1).	  	  Matrix	  metalloproteinases	  and	  cysteine	  proteinases,	  products	  of	  activated	  macrophages,	  localize	  at	  sites	  of	  plaque	  rupture41.	  Several	  of	  these	  enzymes	  digest	  fibrillar	  collagen,	  thus	  reducing	  the	  mechanical	  stability	  of	  the	  plaque41,	  42.	  These	  proteinases	  likely	  render	  plaques	  susceptile	  to	  rupture,	  but	  have	  complex	  effects	  on	  the	  composition	  and	  size	  of	  lesions	  in	  mouse	  experiments.	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Lesional	  cell	  death	  Cell	  death	  may	  also	  predispose	  to	  plaque	  rupture7,	  43.	  	  Smooth	  muscle	  cells	  (SMC)	  synthesize	  the	  bulk	  of	  the	  arterial	  extracellular	  matrix.	  	  Site	  of	  fatal	  plaque	  rupture	  display	  depletion	  of	  SMC	  needed	  to	  repair	  and	  maintain	  the	  collagen	  that	  comprises	  the	  plaque’s	  fibrous	  cap.	  	  Apoptosis	  of	  SMC	  documented	  in	  athromata,	  may	  thus	  lead	  to	  their	  relative	  lack	  at	  sites	  of	  plaque	  rupture.	  	  Rapid	  phagocytosis	  usually	  clears	  the	  remnants	  of	  cells	  that	  have	  undergone	  apoptosis,	  a	  process	  know	  as	  efferocytosis44.	  If	  this	  process	  fails,	  secondary	  necrosis	  ensues,	  contributing	  to	  the	  formation	  of	  the	  plaques	  lipid	  core,	  also	  known	  as	  the	  “necrotic	  core.”	  Computational	  analyses	  indicate	  that	  lipid	  core	  accumulation	  can	  reduced	  the	  mechanical	  integrity	  of	  the	  plaque.	  	  	  Plaque	  necrosis	  results	  from	  death	  of	  lesional	  cells,	  mostly	  macrophages.	  	  Cell	  death	  can	  lead	  to	  necrosis	  by	  at	  least	  two	  mechanisms:	  	  apoptosis	  followed	  by	  defective	  phagocytic	  clearance	  ("efferocytosis")	  of	  the	  apoptotic	  cells;	  and	  a	  process	  called	  primary	  necrosis	  7	  	  .	  	  Macrophage	  apoptosis	  occurs	  in	  lesions	  of	  all	  stages.	  	  A	  number	  of	  plaque	  factors	  are	  likely	  to	  trigger	  lesional	  macrophage	  apoptosis,	  including	  excessive	  inflammation,	  oxidized	  lipids,	  and	  cholesterol,	  often	  in	  combination	  through	  a	  "multi-­‐hit"	  process.	  	  Observational	  data	  in	  human	  atheromata	  and	  molecular-­‐genetic	  causation	  data	  in	  mouse	  models	  of	  advanced	  atherosclerosis	  indicate	  that	  one	  of	  the	  hits	  casued	  by	  these	  factors	  in	  chronic	  endoplasmic	  reticulum	  (ER)	  stress	  45	  .	  	  In	  particular,	  the	  ER	  stress	  effector	  CHOP	  is	  tightly	  associated	  with	  cell	  death	  and	  plaque	  necrosis	  in	  human	  coronary	  artery	  lesions,	  and	  genetic	  deletion	  of	  CHOP	  in	  mice	  protects	  against	  advanced	  lesional	  macrophage	  apoptosis	  and	  plaque	  necrosis	  45	  .	  In	  early	  atherosclerosis,	  the	  apoptotic	  cells	  are	  properly	  cleared	  by	  neighboring	  phagocytes,	  which	  prevents	  post-­‐apoptotic	  necrosis	  and	  triggers	  pro-­‐resolving	  processes	  that	  are	  linked	  to	  efferocytosis	  46.In	  advanced	  plaques,	  however,	  efferocytosis	  is	  defective,	  leading	  to	  cell	  necrosis,	  release	  of	  pro-­‐inflammatory	  damage-­‐associated	  molecular	  patterns	  (DAMPs),	  and	  lack	  of	  efferocytosis-­‐mediated	  pro-­‐resolving	  signaling	  47-­‐49.	  Collectively,	  these	  processes	  promote	  the	  type	  of	  inflammatory,	  necrotic	  lesions	  that	  are	  charcateristic	  of	  vulnerable	  plaques	  (see	  below).	  	  The	  mechanisms	  of	  defective	  efferocytosis	  in	  advanced	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atherosclerotic	  lesions	  are	  not	  known	  and	  are	  likely	  to	  be	  multi-­‐factorial.	  	  A	  recent	  study	  provided	  correlative	  evidence	  in	  human	  atheromata	  suggesting	  a	  role	  for	  ADAM17-­‐mediated	  cleavage	  of	  MerTK,	  a	  macrophage	  efferocytosis	  receptor	  shown	  to	  be	  important	  in	  the	  progression	  of	  murine	  atherosclerosis	  49-­‐51.	  It	  is	  also	  interesting	  to	  note	  that	  defective	  efferocytosis	  is	  a	  cardinal	  sign	  of	  defective	  inflammation	  resolution	  52,	  and	  that	  a	  therapeutic	  strategy	  that	  enhanced	  resolution	  in	  advanced	  murine	  plaques	  markedly	  suppessed	  plaque	  necrosis	  53	  .	  	  Whereas,	  defective	  efferocyosis	  leads	  to	  plaque	  necrosis	  through	  secondary	  necrosis	  of	  uncleared	  apoptotic	  cells,	  cells	  can	  undergo	  another	  process	  in	  which	  necrosis	  develops	  as	  a	  primary	  event.	  	  In	  	  this	  case,	  a	  signaling	  cascade	  involving	  RIP1	  and	  RIP3	  kinases	  is	  involved,	  and	  when	  RIP3	  kinase	  was	  genetically	  targeted	  in	  fat	  fed	  LDL	  receptor	  null	  mice,	  plaque	  necrosis	  was	  partially	  suppressed54.	  	  These	  data	  suggest	  that,	  at	  least	  in	  advanced	  murine	  atheroma,	  both	  secondary	  and	  primary	  apoptosis	  contribute	  to	  plaque	  necrosis.	  Plaque	  erosion	  Plaques	  that	  have	  disrupted	  due	  to	  fibrous	  cap	  fracture	  tend	  to	  have	  a	  large	  lipid	  core30,	  and	  the	  potent	  procoagulant	  tissue	  factor	  localizes	  in	  these	  cores7	  (Fig.	  1).	  Those	  disrupted	  by	  erosion,	  another	  substrate	  for	  thrombus	  formation,	  do	  not	  have	  a	  large	  lipid	  core	  and	  show	  less	  inflammatory	  cell	  accumulation	  than	  fissured	  plaques	  (Fig.	  2).	  Plaques	  frequently	  rupture	  without	  clinical	  manifestations,	  possibly	  reflecting	  variation	  in	  the	  thrombotic	  response	  depending	  on	  the	  thrombogenicity	  of	  exposed	  plaque	  constituents,	  local	  hemorheology,	  shear-­‐induced	  platelet	  activation	  systemic	  clotting	  activity,	  fibrinolytic	  function,	  and	  sensitivity	  of	  the	  end	  organ	  to	  ischemia.	  Plaques	  displaying	  endothelial	  erosion	  seem	  to	  differ	  from	  rupturing	  ones	  in	  some	  important	  aspects29.	  They	  appear	  to	  be	  less	  inflamed	  but	  contain	  proliferating	  smooth	  muscle	  cells,	  abundant	  proteoglycans	  and	  hyaluronan,	  and	  substantial	  neovascularization.	  Therefore,	  pathogenetic	  mechanisms	  may	  differ	  between	  these	  two	  conditions	  and	  we	  will	  consider	  them	  separately.	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Why	  do	  plaques	  rupture?	  Most	  of	  our	  knowledge	  about	  plaque	  rupture	  comes	  from	  studies	  of	  human	  autopsy	  specimens	  and	  surgical	  material.	  Key	  histopathological	  findings	  	  associated	  with	  regions	  of	  fatal	  disruption	  include	  a	  thin	  fibrous	  cap	  (<	  50-­‐60	  microns),	  increased	  signs	  of	  inflammatory	  activity,	  and	  heightened	  amounts	  of	  proteolytic	  enzymes	  	  55-­‐59.	  Therefore,	  inflammatory	  stimuli	  such	  as	  local	  immune	  reactions	  might	  activate	  macrophages,	  mast	  cells	  and	  T	  cells	  to	  release	  cytokines	  that	  inhibit	  cap	  formation	  and	  proteases	  that	  digest	  fibrous	  components	  of	  the	  cap	  (Fig.	  1).	  	  Much	  interest	  has	  focused	  on	  the	  collagenolytic	  action	  of	  matrix	  metalloproteinases	  and	  cysteine	  proteases	  in	  the	  plaque.	  A	  set	  of	  such	  enzymes	  are	  present	  in	  the	  human	  atherosclerotic	  plaque	  and	  has	  shown	  proteolytic	  activity	  in	  culprit	  lesions57,	  60.	  These	  findings	  have	  encouraged	  attempts	  at	  developing	  plaque-­‐stabilizing	  therapies	  by	  targeting	  proteases.	  Several	  excellent	  reviews	  cover	  this	  interesting	  development	  in	  detail61,	  62.	  	  A	  set	  of	  immune	  cytokines	  impacts	  powerfully	  on	  the	  fibrous	  cap	  (Fig.	  1).	  Interferon-­‐gamma,	  a	  proinflammatory,	  macrophage-­‐activating	  cytokine	  produced	  by	  Th1-­‐type	  T	  cells	  and	  NK	  cells,	  inhibits	  collagen	  fiber	  formation,	  causing	  plaques	  to	  adopt	  a	  vulnerable	  phenotype	  with	  reduced	  collagen	  content.	  This	  is	  due	  to	  a	  triple	  action	  of	  interferon-­‐gamma,	  as	  it	  both	  inhibits	  smooth	  muscle	  differentiation24,	  procollagen-­‐I	  gene	  expression23	  and	  the	  collagen	  cross-­‐linking	  enzyme,	  lysyl	  oxidase63.	  	  The	  action	  of	  Th1	  cells	  is	  counterbalanced	  by	  Treg	  cells	  producing	  TGF-­‐beta64	  (Fig.	  1).	  This	  cytokine	  has	  a	  direct,	  fibrogenic	  action	  on	  smooth	  muscle	  cells	  and	  fibroblasts.	  In	  addition,	  it	  inhibits	  Th1	  and	  macrophage	  activity,	  leading	  to	  reduced	  plaque	  inflammation.	  Treg	  also	  enhance	  the	  catabolism	  of	  very-­‐low	  density	  lipoproteins,	  resulting	  in	  reduced	  plasma	  lipid	  levels.	  A	  third	  type	  of	  T	  cells,	  the	  Th17	  cell	  type,	  is	  involved	  in	  wound	  healing	  and	  exerts	  powerful	  fibrogenic	  activity65.	  Th17	  cells	  activated	  in	  the	  context	  of	  atherosclerosis	  promote	  the	  formation	  of	  thick	  collagen	  fibers	  that	  can	  withstand	  the	  mechanical	  assault	  on	  the	  plaque	  exerted	  by	  hemodynamic	  forces66.	  This	  is	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due	  to	  the	  capacity	  of	  the	  signature	  Th17	  cytokine,	  IL-­‐17A,	  to	  promote	  procollagen	  expression	  (Fig.	  1).	  In	  addition	  to	  reducing	  the	  capacity	  of	  the	  tissue	  to	  withstand	  mechanical	  strain,	  immune	  signals	  may	  also	  promote	  atherothrombosis	  by	  increasing	  the	  tendency	  to	  form	  platelet	  aggregates	  and	  clots	  (Fig.	  1).	  The	  TNF/TNF	  receptor	  superfamily	  members,	  CD40	  ligand	  (CD40L,	  CD154)	  and	  CD40,	  may	  have	  particular	  importance	  in	  this	  context.	  CD40L,	  typically	  expressed	  on	  activated	  T	  cells,	  ligates	  CD40	  on	  cells	  of	  the	  macrophage	  lineage.	  This	  stimulation	  triggers	  expression	  of	  tissue	  factor	  as	  well	  as	  matrix	  metalloproteinase	  secretion67.	  In	  addition,	  activated	  platelets	  also	  express	  CD40L	  68	  and	  endothelial	  cells	  exhibit	  its	  receptor	  CD40	  69,	  allowing	  for	  multiple	  heterophilic	  interactions	  that	  may	  promote	  atherothrombosis70,	  71.	  	  	  Lipid	  mediators	  are	  at	  least	  as	  important	  as	  cytokines	  in	  the	  sequence	  of	  events	  leading	  to	  atherothrombosis	  (Fig.	  1).	  The	  prothrombotic	  effect	  of	  thromboxane	  A2	  released	  from	  platelets	  and	  the	  counterbalancing,	  antithrombotic	  effect	  of	  endothelium-­‐derived	  prostaglandin	  I2	  (PGI2,	  a.k.a.	  prostacyclin)	  is	  well	  known,	  crucial	  for	  vascular	  homeostasis,	  and	  the	  target	  of	  aspirin	  used	  in	  cardiovascular	  prevention72,	  73.	  Other	  prostaglandins	  play	  different	  roles	  in	  the	  atherosclerotic	  artery	  wall.	  Thus,	  PGE2	  produced	  by	  several	  cell	  types	  promotes	  vasodilation	  and	  macrophage	  activation	  but	  also	  increases	  expression	  of	  the	  antiinflammatory	  cytokine,	  IL-­‐1074.	  The	  leukotriene	  pathway	  of	  lipid	  mediators	  also	  exerts	  powerful	  effects	  on	  atherosclerosis.	  Leukotriene	  B4	  is	  a	  proinflammatory	  leukotriene	  expressed	  in	  plaques75,	  76.	  Through	  its	  BLT1	  receptor,	  it	  promotes	  plaque	  growth	  and	  enhances	  its	  inflammatory	  properties77.	  It	  also	  increases	  vascular	  restenosis	  after	  endothelial	  injury75.	  5-­‐lipoxygenase-­‐activating	  protein	  (FLAP),	  a	  co-­‐factor	  for	  the	  enzyme	  that	  converts	  arachidonic	  acid	  into	  the	  leukotriene	  pathway,	  is	  upregulated	  in	  plaques	  and	  promotes	  leukotriene(LT)B4	  production78.	  Genetic	  polymorphism	  in	  the	  FLAP	  encoding	  gene,	  ALOX5AP,	  was	  associated	  with	  cardiovascular	  disease	  in	  several	  genetic	  studies79,	  although	  it	  did	  not	  turn	  out	  to	  be	  a	  major	  genetic	  risk	  factor	  in	  genome-­‐wide	  association	  studies.	  However,	  this	  does	  not	  rule	  out	  a	  possible	  role	  for	  leukotriene	  signaling	  in	  cardiovascular	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disease.	  As	  many	  patients	  with	  asthma	  are	  treated	  with	  leukotriene	  receptor	  blockers,	  long-­‐term	  follow-­‐up	  of	  these	  individuals	  permits	  an	  assessment	  of	  the	  importance	  of	  leukotriene	  signaling	  in	  cardiovascular	  disease80.	  A	  population-­‐based	  Swedish	  study	  of	  7	  million	  cases	  revealed	  that	  those	  treated	  with	  the	  leukotriene	  receptor	  blocker,	  montelukast	  had	  a	  35%	  reduced	  risk	  of	  recurrent	  stroke	  and	  myocardial	  infarction80.	  Lipoxins	  and	  resolvins	  produced	  in	  the	  12/15-­‐lipoxygenase	  pathway	  counterbalance	  the	  proinflammatory	  effects	  of	  leukotrienes	  and	  may	  inhibit	  atherosclerosis	  and	  its	  clinical	  complications	  81.	  In	  line	  with	  this	  notion,	  targeting	  the	  lipoxin	  receptor	  FPR2/ALX	  by	  genetic	  abrogation	  leads	  to	  features	  of	  reduced	  plaque	  stability	  82.	  Further	  studies	  will	  be	  required	  to	  clarify	  the	  role	  of	  pro-­‐	  and	  anti-­‐inflammatory	  lipoxygenase	  products	  in	  atherosclerosis.	  Clinical	  studies	  have	  associated	  ischemic	  atherothrombotic	  events	  such	  as	  MI	  and	  stroke	  with	  infections.	  Acute	  infections,	  via	  elicitation	  of	  systemic	  cytokines,	  may	  elicit	  an	  “echo”	  of	  inflammatory	  activation	  in	  the	  plaque,	  leading	  to	  bursts	  of	  proinflammatory,	  proteolytic,	  and	  prothrombotic	  activity,	  although	  we	  currently	  lack	  definitive	  evidence	  to	  confirm	  such	  a	  chain	  of	  events83.	  The	  lack	  of	  suitable	  animal	  models	  has	  hampered	  research	  on	  plaque	  disruption.	  Although	  under	  circumstances	  that	  should	  promote	  thrombosis	  on	  plaques	  in	  rodents,	  such	  experiments	  yielded	  a	  low	  incidence	  of	  thrombosis	  and	  lack	  of	  linear	  relationship	  between	  events	  and	  histopathological	  findings	  such	  as	  “buried	  caps”84-­‐86.	  Such	  studies	  have	  not	  generally	  dealt	  with	  coronary	  arteries,	  rather	  the	  aorta	  or	  its	  large	  caliber	  branches.	  	  Yet,	  more	  recent	  work	  has	  described	  promising	  experimental	  preparations	  that	  may	  be	  more	  suitable	  for	  addressing	  mechanisms	  of	  plaque	  rupture87.	  In	  genetically	  hypercholesterolemic	  mutant	  mice,	  several	  interventions	  can	  precipitate	  rupture	  of	  existing	  atherosclerotic	  plaques,	  for	  example	  virally-­‐directed	  local	  overexpression	  of	  an	  active	  form	  of	  the	  MMP	  stromelysin,	  	  the	  long-­‐term	  infusion	  of	  angiotensin	  II88,	  placement	  of	  a	  cuff	  around	  the	  carotid	  artery89,	  partial	  ligation	  of	  this	  artery90	  or	  increasing	  elastin	  fragmentation	  through	  a	  “knock-­‐in”	  mutation	  in	  the	  fibrillin-­‐1	  gene91.	  Yet,	  none	  of	  these	  preparations	  induces	  standardized	  plaque	  ruptures	  at	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a	  given	  time	  in	  a	  controlled	  manner.	  Instead,	  they	  increase	  the	  tendency	  for	  the	  plaque	  to	  rupture,	  and	  heal,	  spontaneously.	  	  Signs	  of	  plaque	  rupture	  include	  intraplaque	  haemorrhage,	  fractured	  cap	  fibers,	  and	  multi-­‐layered	  “buried”	  caps92.	  Enumeration	  of	  these	  signs	  by	  microscopy	  permits	  quantification	  of	  the	  phenomenon.	  Such	  methods	  have	  obvious	  limitations	  but	  may	  permit	  investigators	  to	  assess	  the	  effects	  of	  various	  treatments	  on	  the	  tendency	  for	  plaques	  to	  rupture.	  	  The	  contrived	  nature	  of	  these	  manipulations,	  however,	  limits	  the	  generalizability	  of	  such	  experiments.	  	  For	  example,	  a	  blocker	  of	  angiotensin	  II	  should	  limit	  disruptions	  produced	  by	  infusions	  of	  this	  mediator,	  and	  MMP	  inhibitors	  will	  reduce	  the	  consequences	  of	  stromelysin	  overexpression	  with	  no	  predictive	  value	  for	  the	  effects	  of	  these	  interventions	  on	  plaque	  rupture	  in	  humans.	  
Why	  does	  the	  endothelium	  erode?	  	  Mechanisms	  instigating	  endothelial	  erosion	  have	  been	  unclear.	  However,	  recent	  studies	  point	  to	  a	  role	  for	  innate	  immunity	  in	  this	  process	  (Fig.	  2).	  Endothelial	  cells	  overlying	  atherosclerotic	  lesions	  abundantly	  express	  the	  pattern	  recognition	  receptor,	  Toll-­‐like	  receptor-­‐2	  (TLR2)11.	  	  Ligation	  of	  this	  receptor	  results	  in	  endothelial	  apoptosis	  in	  a	  process	  accelerated	  by	  polymorphonuclear	  leukocytes,	  a	  cell	  type	  found	  at	  sites	  of	  fatal	  plaque	  erosion93.	  TLR2	  ligands	  include	  the	  extracellular	  molecule	  hyaluronan	  as	  well	  as	  components	  of	  Gram-­‐positive	  bacteria94,	  therefore	  endogenous	  as	  well	  as	  infectious	  factors	  may	  operate	  to	  promote	  atherothrombosis	  through	  this	  mechanism93.	  Stressful	  events	  also	  associate	  with	  acute	  ischemic	  events.	  For	  example,	  the	  incidence	  of	  myocardial	  infarction	  often	  rises	  shortly	  after	  major	  sports	  events	  (particularly	  in	  males),	  and	  peaked	  after	  stressful	  events	  such	  as	  a	  major	  earthquake95,	  96.	  This	  association	  may	  result	  from	  acute	  changes	  in	  local	  hemodynamics	  of	  the	  atherosclerotic	  artery.	  Exposure	  of	  atherosclerotic	  mice	  to	  stressful	  stimuli	  led	  to	  endothelin-­‐dependent	  vasoconstriction	  that	  preceded	  thrombosis	  and	  myocardial	  ischemia,	  possibly	  because	  the	  vasoconstrictive	  episode	  had	  caused	  endothelial	  erosion56	  .	  Likewise,	  infusion	  of	  spasmogenic	  stimuli	  in	  MI-­‐prone	  rabbits	  elicited	  occasional	  coronary	  artery	  thrombi	  resembling	  human	  superficial	  erosion97.	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How	  can	  plaques	  be	  stabilized?	  Abundant	  experimental	  and	  some	  clinical	  data	  using	  MRI	  or	  intravascular	  imaging	  suggest	  that	  lipid	  lowering,	  and	  statin	  therapy	  in	  particular	  may	  alter	  plaque	  properties	  implicated	  in	  susceptibility	  to	  rupture.	  	  Several	  other	  approaches	  may	  stabilize	  plaques	  (Fig.	  3).	  None	  of	  them	  have	  entered	  clinical	  trials	  on	  the	  indication	  to	  stabilize	  plaques,	  in	  part	  due	  to	  the	  difficulties	  in	  identifying	  vulnerable,	  ruptured,	  eroded	  and	  thrombosed	  lesions	  in	  the	  living	  patient.	  Current	  progress	  in	  in	  vivo	  imaging	  techniques	  might	  enable	  such	  trials	  in	  the	  future.	  
Conclusion	  	  Atherosclerosis	  associates	  strongly	  with	  systemic	  risk	  factors	  (e.g.	  high	  LDL,	  hypertension,	  diabetes),	  yet	  the	  lesions	  distribute	  multifocalally.	  Most	  plaques	  remain	  silent	  throughout	  life	  but	  certain	  individual	  lesions	  may	  provoke	  	  thrombotic	  complication	  and	  ischemia,	  resulting	  in	  life-­‐threatening	  complications.	  The	  discovery	  of	  plaque	  rupture	  and	  endothelial	  erosion	  as	  two	  main	  causes	  of	  atherothrombosis	  helps	  us	  to	  understand	  why	  this	  very	  chronic	  condition	  manifest	  clinically	  in	  an	  episodic	  and	  unpredictable	  fashion.	  Further	  studies	  have	  clarified	  that	  inflammation,	  proteolysis,	  and	  reduced	  collagen	  fiber	  content	  predispose	  to	  plaque	  rupture,	  whereas	  endothelial	  erosion	  followed	  by	  neutrophil	  infiltration	  typically	  complicates	  lesions	  of	  a	  distinct	  morphology.	  	  Lack	  of	  animal	  preparations	  that	  develop	  disruption	  of	  atherosclerotic	  plaques	  has,	  however,	  hampered	  progress	  in	  mechanistic	  research	  on	  atherothrombosis.	  Similarly,	  limitations	  of	  non-­‐invasive	  in	  vivo	  imaging	  of	  so	  called	  “vulnerable	  plaques”	  in	  humans	  has	  hampered	  clinical	  work	  in	  this	  domain.	  Recent	  progress	  in	  both	  these	  areas	  may	  address	  these	  issues	  and	  aid	  the	  development	  and	  evaluation	  of	  plaque-­‐stabilizing	  therapies	  beyond	  lipid	  lowering	  in	  the	  forthcoming	  years.	  The	  many	  unanswered	  questions	  in	  this	  field	  provide	  ample	  opportunity	  for	  future	  research,	  and	  may	  yield	  avenues	  to	  improve	  patient	  outcomes.	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Figure	  legends:	  
	  
Figure	  1.	  Mechanisms	  of	  plaque	  rupture.	  Activated	  macrophages	  and	  Th1	  cells	  produce	  metalloproteinases	  and	  cytokines	  that	  hamper	  the	  tensile	  strength	  of	  the	  collagen	  cap.	  Several	  proinflammatory	  cytokines	  including	  interferon-­‐g	  (IFNg)	  and	  tumor	  necrosis	  factor	  (TNF),	  as	  well	  as	  CD40/CD40L	  cell	  surface	  receptors	  of	  the	  TNF	  superfamily	  promote	  an	  inflammatory	  state	  that	  enhance	  cell	  death	  and	  prothrombotic	  activity	  in	  the	  plaque.	  When	  the	  cap	  no	  longer	  can	  withstand	  the	  mechanical	  force	  of	  the	  blood	  pressure,	  superficial	  fissures	  are	  formed	  in	  the	  plaque.	  Exposure	  of	  the	  plaque’s	  inner	  core	  with	  its	  thrombogenic	  material	  rapidly	  triggers	  platelet	  activation,	  humoral	  coagulation,	  and	  the	  formation	  of	  a	  thrombus	  that	  may	  either	  occlude	  the	  artery	  at	  the	  site	  of	  plaque	  rupture,	  or	  dissociate	  as	  an	  embolus	  and	  occlude	  the	  arterial	  lumen	  at	  a	  site	  downstream	  of	  the	  ruptured	  plaque.	  	  Counteracting	  all	  these	  proinflammatory	  and	  tissue-­‐destructive	  signals,	  subsets	  of	  macrophages	  and	  T	  cells	  produce	  anti-­‐inflammatory	  molecules	  that	  counteract	  vascular	  inflammation	  and	  reduce	  the	  risk	  for	  plaque	  rupture	  and	  atherothrombosis.	  Among	  them,	  transforming	  growth	  factor-­‐b	  (TGF-­‐b)	  and	  interleukin-­‐10	  (IL-­‐10)	  inhibit	  inflammation	  and	  immune	  cell	  activation.	  In	  addition,	  TGF-­‐b	  has	  fibrogenic	  properties	  that	  it	  shares	  with	  IL-­‐17A	  produced	  by	  Th17	  cells.	  The	  resolution	  of	  plaque	  inflammation	  depends	  not	  only	  on	  anti-­‐inflammatory	  signals	  but	  also	  on	  resolving	  mediators	  such	  as	  eicosanoids	  of	  the	  resolvin	  type	  and	  Annexin	  I,	  both	  of	  which	  ligate	  the	  FPR/ALX	  receptor.	  EC,	  endothelial	  cell;	  SMC,	  smooth	  muscle	  cell;	  MΦ,	  macrophage;	  MMP,	  metalloproteinase;	  TXA2,	  thromboxane	  A2;	  PGI2,	  prostaglandin	  I2	  (prostacyclin).	  	  
Figure	  2.	  Mechanisms	  of	  plaque	  erosion.	  Endothelial	  cells	  of	  atherosclerotic	  plaques	  commonly	  express	  Toll-­‐like	  receptor	  –2	  (TLR2)	  that	  can	  ligate	  both	  Gram-­‐positive	  toxins	  (G+	  toxins)	  of	  bacterial	  pathogens	  and	  hyaluronan	  released	  from	  the	  extracellular	  matrix.	  TLR2	  ligation	  can	  trigger	  endothelial	  dysfunction	  with	  endoplasmic	  reticulum	  stress	  and	  apoptosis.	  Such	  reactions	  are	  further	  enhanced	  by	  neutrophil	  attack	  on	  the	  endothelium.	  As	  a	  result,	  endothelial	  cells	  may	  detach,	  exposing	  the	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subendothelial	  matrix	  with	  its	  thrombogenic	  components.	  Activated	  neutrophils	  contribute	  to	  a	  prothrombotic	  state	  by	  releasing	  a	  set	  of	  proteases	  including	  neutrophil	  elastase	  and	  by	  forming	  neutrophil	  extracellular	  traps	  (NETs)	  that	  can	  damage	  endothelial	  cells,	  trap	  leukocytes,	  and	  enhance	  thrombosis.	  PAD4,	  Peptide	  arginine	  deaminase-­‐4,	  a	  component	  of	  NETs.	  	  	  
Figure	  3.	  Therapy	  targets	  for	  prevention	  of	  atherothrombosis.	  Reduction	  of	  LDL	  (and	  other	   large	   lipoproteins)	  by	   lipid-­‐lowering	   therapy,	  and	  prevention	   of	   LDL	   retention	   in	   the	   artery	  wall,	   both	   act	   to	   reduce	   cholesterol	  accumulation,	   an	   initiator	   of	   atherosclerosis.	   Stimulation	   of	   immunoregulatory	  mechanisms	  reduce	  vascular	   inflammation;	  they	  include	  administration	  of	  anti-­‐inflammatory	   cytokines,	   enhancing	   Treg	   cells,	   and	   vaccination	   to	   elicit	  atheroprotective	   immunity.	   Mediators	   of	   resolution	   include	   resolvin-­‐type	  eicosanoids,	  peptide	  mimetics	  of	  Annexin	  I,	  and	  other	  substances.	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Figure	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